Humanization of rabbit antibodies using a universal antibody framework
US-11858981-B2 · Jan 2, 2024 · US
RANKL antibody-PTH/PTHrP chimeric molecules
US8992925B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8992925-B2 |
| Application number | US-59962906-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 13, 2006 |
| Priority date | Nov 14, 2005 |
| Publication date | Mar 31, 2015 |
| Grant date | Mar 31, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.
First claim
Opening claim text (preview).
We claim: 1. A receptor activator of NF-κB ligand (RANKL) antibody-parathyroid hormone/parathyroid hormone related protein (PTH/PTHrP) chimeric molecule, comprising: (a) an antibody that binds to RANKL; and (b) a PTH/PTHrP peptide comprising a PTH/PTHrP modulating domain; wherein the PTH/PTHrP peptide is operably linked to the antibody. 2. The RANKL antibody-PTH/PTHrP chimeric molecule of claim 1 , wherein the PTH/PTHrP peptide is operably linked t…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8992925B2 cover?
- Chimeric molecules comprising receptor activator of NF-κB ligand (RANKL) antibodies and parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) peptides are described. Compositions and methods for the treatment of bone diseases are also described.
- Who is the assignee on this patent?
- Kostenuik Paul, Shen Wenyan, Boone Thomas C, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/241. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).